Published in final edited form as:

Biochemistry. 2011 April 12; 50(14): 3014–3024. doi:10.1021/bi101728y.

A Novel Intermediate in the Reaction of Seleno CYP119 with *m*-Chloroperbenzoic Acid†

Santhosh Sivaramakrishnan¹, Hugues Ouellet¹, Jing Du², Kirsty J. McLean³, Katalin F. Medzihradszky¹, John H. Dawson², Andrew W. Munro³, and Paul R. Ortiz de Montellano^{1,*}

¹Department of Pharmaceutical Chemistry, University of California, San Francisco, CA 94158-2517

²Department of Chemistry and Biochemistry, University of South Carolina, Columbia, SC 29208

³Manchester Interdisciplinary Biocentre, Faculty of Life Sciences, University of Manchester, 131 Princess Street, Manchester M1 7DN, United Kingdom

Abstract

Cytochrome P450 mediated monooxygenation generally proceeds via a reactive ferryl intermediate coupled to a ligand radical [Fe(IV)=O]⁺ referred to as Compound I (Cpd I). The proximal cysteine thiolate ligand is a critical determinant of the spectral and catalytic properties of P450 enzymes. To explore the effect of increased electron donation by the proximal ligand in the P450 catalytic cycle, we recently reported successful incorporation of SeCys into the active site of CYP119, a thermophilic cytochrome P450. Here we report relevant physical properties of SeCYP119 and a detailed analysis of the reaction of SeCYP119 with *m*-chloroperbenzoic acid. Our results indicate that the selenolate anion reduces rather than stabilizes Cpd I and also protects the heme from oxidative destruction, leading to the generation of a new stable species with an absorbance maximum at 406 nm. This stable intermediate can be returned to the normal ferric state by reducing agents and thiols, in agreement with oxidative modification of the selenolate ligand itself. Thus, in the seleno protein, the oxidative damage shifts from the heme to the proximal ligand, presumably because (a) increased electron donation more efficiently quenches reactive species such as Cpd I, and (b) the protection of the thiolate ligand provided by the protein active site structure is insufficient to shield the more oxidizable selenolate ligand.

Cytochrome P450 enzymes are heme containing monooxygenases that catalyze a variety of physiologically relevant oxidative reactions, including hydroxylation, epoxidation, and heteroatom oxidation (1). The P450 catalytic cycle involves the generation of several intermediates, at least one of which transfers an oxygen atom to the substrate (2). Specifically, [Fe(IV)=O]⁺, a high-valent iron (IV) oxo intermediate coupled to a ligand radical, also known as Compound I (Cpd I), is thought to be the immediate species responsible for substrate oxidation (1,2). Recent work by Green and coworkers has provided strong confirmatory support for the role of this Cpd I species (3).

†This research was supported by National Institutes of Health grants GM25515 (to POM) and NCRR P41RR001614 and RR019934 (to the Bio-Organic Biomedical Mass Spectrometry Resource at UCSF (director A.L. Burlingame).

*To whom correspondence should be addressed: 600 16th St., University of California, San Francisco, CA 94158. Telephone: (415) 476-2903. Fax: (415) 502-4728. ortiz@cgl.ucsf.edu.

SUPPORTING INFORMATION AVAILABLE

Supporting information available for the MCD spectra, redox potential data, rapid scan absorbance spectra and the SVD analysis for the reaction of SeCYP119 with sub-stoichiometric amount of *m*CPBA (1.25 μM), and LC/MS/MS spectra of the trypsin digested P406 species. This material is available free of charge via the Internet at <http://pubs.acs.org>.

The iron of the prosthetic heme in the P450 active site is coordinated on the proximal side to a cysteine thiolate ion (4,5). This unique feature distinguishes P450 enzymes from classical peroxidases and catalases and is largely responsible for the unique spectral and catalytic properties of this class of enzymes. Earlier attempts to modulate the electron donating ability of the proximal residue in a P450 by mutating the proximal thiol to a histidine (6,7), serine (8), or methionine (9) resulted in loss of both the signature spectral characteristics and catalytic activities of the P450 enzymes. These results, all of which involved less electron donating iron ligands, confirm the importance of the proximal cysteine in P450 catalysis. However, substitution of a stronger electron donor ligand has not been examined and would be potentially informative, as enhanced electron donation has been computationally predicted to both increase the rate of formation and decrease the rate of decomposition of the Cpd I intermediate (10).

CYP119 from *Sulfolobus acidocaldarius* is a thermophilic protein that is relatively stable to both high temperature and pressure (11). The rigid structure and remarkable physical properties of CYP119, combined with the fact that the only cysteine in its sequence is the heme iron ligand, make it an attractive system for selenocysteine substitution. Several methods exist for the incorporation of a selenocysteine into a protein (12–14). We have successfully expressed selenocysteine-substituted CYP119, SeCYP119 (15), by expressing the protein in the presence of selenocysteine using auxotrophic *BL21(DE3)CysE* cells that cannot synthesize cysteine due to a mutation in their *CysE* gene (16). Hilvert and coworkers independently reported the expression of selenocysteine-substituted CYP101A1 from *Pseudomonas putida* using an alternative approach (17). Both of these selenocysteine-substituted enzymes are stable and retain their basic spectral and catalytic properties. Specifically, SeCYP119 displays UV-vis and resonance Raman spectra that match those of the WT protein, confirming the presence of a six-coordinated active site heme with a water molecule as the sixth ligand. Furthermore, the catalytic activity of the seleno protein in the shunt pathway with H₂O₂ as a surrogate oxidant is comparable to that of the WT enzyme, suggesting that the proximal selenocysteine substitution preserves the overall catalytic properties of the enzyme.

Here we report physical properties of SeCYP119 relevant to its catalytic function and provide the first analysis of the reaction of any selenocysteine-substituted P450 enzyme with a surrogate oxidizing agent. Our results with *m*-chloroperbenzoic acid (*m*CPBA) and peroxyxynitrite (PN) as the oxidizing partners clarify the role of electron donation by the proximal ligand on P450 catalysis and identify a novel intermediate.

EXPERIMENTAL PROCEDURES

Materials and Methods

Buffer salts and chemicals were purchased from Fisher Scientific. *L*-Selenocysteine and amino acids were purchased from Sigma-Aldrich. Unless otherwise specified, all other reagents were also purchased from Sigma-Aldrich (St. Louis, MO). Water was purified with a Milli-Q® purification system (Millipore). All buffers and supplements were prepared using Millipore® water and the supplements were filter sterilized using a 0.22 µm filter. Auxotrophic *BL21(DE3)CysE* cells were kindly provided by Dr. Marie-Paule Strub (National Institutes of Health). The cells were made competent by a typical RbCl method and tested for their inability to grow in the absence of added cysteine, in both LB and minimal media plates. HiPrep™ Q-FF and HisTrap Ni-NTA™ pre-packed columns were purchased from GE Healthcare. The SeCYP119 protein was expressed and purified according to the previously reported protocol (15), except that chloramphenicol (10 mgL⁻¹) was added to the culture (at the OD₆₀₀ = 1.2) and incubated for a further 10 min at 37 °C immediately before washing the cells. This method resulted in more than 80% replacement

of cysteine with selenocysteine. The concentration of SeCYP119 was determined from its CO-difference spectrum using $\epsilon_{(456-490)\text{ nm}} = 91\text{ mM}^{-1}\text{ cm}^{-1}$.

All UV-vis spectrophotometric measurements were performed on a CARY 1E UV-vis spectrophotometer (Varian Inc.). The concentrations of *m*CPBA used in the assays were standardized using a triiodide assay ($\epsilon_{353\text{ nm}} = 25.5\text{ mM}^{-1}\text{ cm}^{-1}$) (18). All oxidation reactions were carried out using a freshly prepared *m*CPBA stock in acetone. Peroxynitrite (PN) was prepared according to a published procedure (19) and the concentration was determined by UV-vis spectroscopy ($\epsilon_{302\text{ nm}} = 1670\text{ M}^{-1}\text{ cm}^{-1}$). The PN was aliquoted and stored at $-80\text{ }^{\circ}\text{C}$ until used. The alkaline pyridine hemochromogen assay was carried out as reported earlier (20). Rapid mixing experiments were performed using an SF-61 DX2 double mixing stopped-flow system (Hi-Tech Scientific, Bradford-on-Avon, UK) equipped with a photodiode array detector. All reactions were carried out at $10\text{ }^{\circ}\text{C}$ unless reported otherwise. The kinetic data were analyzed using the Pro-K software (Applied Photophysics, UK).

MCD spectra were measured at a magnetic field strength of 1.41 T with a JASCO J815 spectropolarimeter equipped with a JASCO MCD-1B electromagnet and interfaced with a Silicon Solutions PC through a JASCO IF-815-2 interface unit. UV-visible (UV-vis) spectra were recorded using a Cary 400 spectrophotometer interfaced to a Dell PC. All spectral measurements were obtained in 50 mM potassium phosphate buffer (pH 7.4) at $4\text{ }^{\circ}\text{C}$ using a 0.2-cm cuvette (protein concentration about $25\text{ }\mu\text{M}$). Data acquisition and manipulation with Cary or JASCO software has been previously described (21). UV-vis spectra were recorded before and after MCD measurements to verify sample integrity. Reduction of the heme complexes was achieved by adding a small amount of solid or a few μL of a concentrated (25 mg/mL) sodium dithionite solution after degassing the protein under N_2 in a septum sealed cuvette.

Oxidation of SeCYP119 to Generate the P406 Species

In a typical experiment, a solution of SeCYP119 ($10\text{ }\mu\text{M}$) in potassium phosphate buffer (100 mM, pH 6.2) was treated with an equal volume of phosphate buffer containing *m*CPBA ($100\text{ }\mu\text{M}$) to obtain the oxidized SeCYP119 solution (final concentrations: SeCYP119, $5\text{ }\mu\text{M}$; *m*CPBA, $50\text{ }\mu\text{M}$) with an UV-vis absorption maximum at 406 nm.

Kinetics of the *m*CPBA-Mediated Oxidation of P450 Proteins

In a typical experiment, a solution of protein ($10\text{ }\mu\text{M}$) in potassium phosphate buffer (100 mM, pH 6.2) was rapidly mixed with an equal volume of varying concentrations of *m*CPBA solution in the same buffer (1.25, 2.5, 5, 10, 50 and $100\text{ }\mu\text{M}$) at $10\text{ }^{\circ}\text{C}$ in the stopped-flow mixing unit. The resulting reaction was followed with a diode array monitor. The reactions were conducted such that the final concentrations of *m*CPBA were 0.125, 0.25, 0.5, 1.0, 5 and 10 times that of the final protein concentration ($5\text{ }\mu\text{M}$). The changes in absorbance at 416 and 370 nm, corresponding to the ferric and Cpd I species, were monitored (22).

Kinetics of the Reactions of P450 Proteins with Peroxynitrite (PN)

In a typical experiment, a solution of protein ($6\text{ }\mu\text{M}$) in phosphate buffer (100 mM, pH 7.0) was rapidly mixed with an equal volume of varying concentrations of freshly made PN solution in 10 mM NaOH (1, 1.5, 2, 3 and 4 mM) at $10\text{ }^{\circ}\text{C}$ in the stopped-flow instrument (final concentrations: enzyme, $3\text{ }\mu\text{M}$; PN, 0.5, 0.75, 1, 1.5 and 2 mM). The spectrum was scanned from 300 to 700 nm using a diode-array monitor. Changes in absorbance at 416 and 430 nm corresponding to the ferric and Cpd II species were monitored (23).

Testing for the Presence of Covalent Heme Modifications

The P406 species generated at the room temperature (24 °C) was injected onto a C4 column in HPLC and eluted using a previously reported method (24) with water (0.1% TFA) and acetonitrile (0.1% TFA) as the solvents. The eluant was monitored at 280 and 400 nm for the protein and heme, respectively.

Determination of the Catalytic Activity of P406 by the Peroxide Shunt Pathway

In a typical assay, SeCYP119 (1.2 μ M) was pre-incubated for 5 min with *m*CPBA (12 μ M) in potassium phosphate buffer (50 mM, pH 7.4). To this was added lauric acid (100 μ M) and the resulting mixture was incubated either at room temperature (23 °C) or at 50 °C for 40 min (final volume, 250 μ L). Alternatively, excess *m*CPBA (100 μ M) or hydrogen peroxide (10 mM) was added to the reaction mixture after the addition of lauric acid to facilitate the oxidation, and the resulting mixture was then incubated as before. The reactions were worked-up, derivatized and analyzed on a GC-MS instrument as reported earlier (15).

Trypsin Digestion and Mass Spectrometric Analysis of P406

WT and SeCYP119 proteins (~450 pmoles) were oxidized under anaerobic conditions (anaerobic chamber) with a 10-equivalent excess of *m*CPBA. Formation of the P406 species in the oxidation of SeCYP119 was confirmed by UV-vis spectroscopy. The resulting mixture was incubated for 5 min and the excess *m*CPBA was removed by a spin-column (10k MWCO, Amicon ultracentrifugal device, Millipore®, USA). The protein was then reconstituted in ammonium bicarbonate buffer (25 mM) and alkylated using iodoacetamide (10 mM) in the dark for 30 min at 24 °C. The samples were denatured with guanidine hydrochloride (final concentration, 4 M) and another aliquot of alkylating agent was added, and the resulting mixtures were incubated for a further 1 h in the dark. Excess iodoacetamide was quenched with DTT (20 mM in NH_4HCO_3) and the reactions were diluted with ammonium bicarbonate (500 μ L). The samples were then taken out of the glove box and digested with trypsin (2.5 μ g in NH_4HCO_3) at 37 °C overnight, concentrated in the speed vac to a final volume of 50 μ L, and analyzed by LC/MS/MS using a linear iontrap FT-ICR hybrid tandem mass spectrometer (LTQ-FT, Thermo Fisher Scientific, Bremen, Germany), measuring the precursor masses with high resolution and high mass accuracy in the magnet while performing the CID experiments in the linear trap.

Redox Potentiometry

SeCYP119 redox titrations were performed in a Belle Technology glove box under a nitrogen atmosphere, as described previously (25). SeCYP119 (~5 μ M in 5 ml of 100 mM potassium phosphate, 10% glycerol, pH 7.0) was titrated electrochemically using sodium dithionite as reductant and potassium ferricyanide as oxidant (26). Mediators were added to facilitate electrical communication between the enzyme and electrode (2 μ M phenazine methosulfate, 7 μ M 2-hydroxy-1,4-naphthoquinone, 0.3 μ M methyl viologen, and 1 μ M benzyl viologen, to mediate in the range from +100 to -480 mV) (27). Spectra (250–800 nm) were recorded using a Cary UV-50 Bio UV-visible scanning spectrophotometer. The electrochemical potential of the solution was measured using a Mettler Toledo SevenEasy meter coupled to a Pt/Calomel electrode (ThermoRussell Ltd.) at 25 °C. The electrode was calibrated using the $\text{Fe}^{3+}/\text{Fe}^{2+}$ -EDTA couple as a standard (+108 mV). A factor of +244 mV was used to correct relative to the standard hydrogen electrode. Redox titrations were performed in both reductive and oxidative directions to ensure that the redox processes were fully reversible and hysteretic effects were not observed. There was a clear biphasic dependence of heme absorption change *versus* applied potential, and data were fitted to a 2-electron Nernst function (Equation 1, using Origin software, OriginLab, Northampton MA)

to derive midpoint reduction potential data for the SeCYP119 heme iron $\text{Fe}^{3+}/\text{Fe}^{2+}$ transition.

$$Abs = \frac{a10^{(E-E_1/59)} + b + c10^{(E_2-E/59)}}{1 + 10^{(E-E_1/59)} + 10^{(E_2-E/59)}} \quad (\text{Equation 1})$$

In Equation 1, *Abs* is the observed absorbance value at applied potential *E*, *a* is the absorbance of the fully oxidized (ferric) heme, *b* is the absorbance on completion of the reduction of the first heme species and *c* is the absorbance on reduction of the second heme species. *E*₁ and *E*₂ are the corresponding midpoint potentials, respectively, for these heme iron $\text{Fe}^{3+}/\text{Fe}^{2+}$ transitions.

RESULTS

Thermal Stability of SeCYP119

WT CYP119 is a thermophilic enzyme that is stable at up to ~80 °C (28). To determine whether replacement of the proximal cysteine by a selenocysteine alters the thermal stability, the WT protein and SeCYP119 were pre-incubated in parallel at temperatures ranging from 50 to 90 °C for 60 min, after which the absorbance maximum of the ferrous-CO complex was measured by difference spectroscopy at room temperature. The SeCYP119 was stable at up to 70 °C with no significant heme loss, but lost about 40% of its P450 content at 80 °C and more than 70% after incubation at 90 °C (Fig. S1, Supporting info.). The proteins were partially precipitated upon incubation at the higher temperatures (80 and 90 °C). Overall, the thermal stability of SeCYP119 was comparable to that of WT CYP119, indicating that the active site of the seleno mutant is structurally intact even at higher temperatures.

Comparison of the MCD Spectrum of the WT and SeCYP119 Proteins

MCD spectra of ferric and ferrous SeCYP119 were investigated to verify whether the substitution of selenocysteine (SeCys) changed the nature of the heme coordination compared to the WT protein. Figure S2 (Supporting info.) shows a comparison of the MCD and UV-vis absorption spectra of ferric WT and SeCYP119 proteins. The overall spectral patterns are very similar to each other, indicating the presence of a six-coordinated ferric heme with water as the sixth ligand. Similarly, addition of dithionite at 4 °C, reduced the SeCYP119 slowly over one hour to yield an MCD and UV-vis spectra identical to that of the WT protein (Fig. S3, Supporting info.), suggesting that the SeCys incorporation has not significantly altered the heme environment.

Redox Potential of SeCYP119

Replacement of the proximal cysteine with a selenocysteine is expected to decrease the redox potential of the protein because selenium is more electron donating and has a lower redox potential than sulfur (16,29,30). Indeed, a redox titration of SeCYP119 progressed with conversion of the ferric heme iron to the ferrous state and a concomitant shift in the Soret feature from ~416.5 to ~403 nm. In the Q-band region the distinct α - and β -bands were lost on reduction in favor of a merged band at ~550 nm. These spectral shifts are consistent with retention of the selenocysteine iron coordination in the reduced species.

Data fitting at a number of different wavelengths showed the process of heme iron reduction to occur in two distinct phases. These could be fitted using a 2-electron Nernst function (Equation 1), and analysis of the data at different wavelengths gave consistent values for the midpoint potentials (e.g. at 384 nm $E_1 = -62 \pm 5$ mV, $E_2 = -72 \pm 3$ mV; at 403 nm [near the

maximum for the ferrous heme iron] $E_1 = -67 \pm 5$ mV, $E_2 = -265 \pm 3$ mV; and at 551 nm [at the Q-band maximum in the ferrous state] $E_1 = -57 \pm 5$ mV, $E_2 = -266 \pm 3$ mV). The data indicate a heterogeneous population of heme centers in the SeCYP119 and showed that the ferrous enzyme could be re-oxidized to the ferric form without hysteresis in the dependence of the optical spectrum on the applied potential (Fig. S4, Supporting info.).

Kinetics of mCPBA-Mediated Oxidation of SeCYP119

SeCYP119 was oxidized using the shunt pathway to investigate the influence of an electron rich proximal SeCys on the kinetics of formation and decay of the Cpd I intermediate. For this purpose, we utilized *m*CPBA as the oxidant in sub-stoichiometric and stoichiometric amounts to minimize heme bleaching and unwanted oxidative reactions, as it has been previously reported to generate Cpd I in reaction with WT CYP119 (22). Results from the rapid scan spectrum were analyzed with the model $A + B \rightarrow C \rightarrow D$ in which species A and B correspond to the starting ferric form and *m*CPBA, respectively. The other species are defined based on the specific reaction, as discussed below. Our results provided no spectral evidence for Cpd I accumulation in the *m*CPBA-mediated oxidation of SeCYP119, but a new stable species with an absorption maximum at 406 nm and a broad shoulder centered at 625 nm was observed.

Oxidation with Sub-Stoichiometric Amounts of mCPBA

Initially, we tested the oxidation of SeCYP119 with increasing sub-stoichiometric concentrations of *m*CPBA (enzyme, 5 μ M; *m*CPBA, 0.625, 1.25, 2.5 μ M in 100 mM phosphate buffer, pH 6.2) by stopped-flow spectroscopy. Interestingly, no significant changes were noticed in the rapid scan spectrum. Specifically, no increase in absorbance at 369 nm, corresponding to Cpd I, was observed (Fig. S5, Supporting info.). SVD analysis of the rapid scan data with the $A + B \rightarrow C \rightarrow D$ model revealed a species C that resembled the starting ferric protein, presumably resulting from rapid conversion of the intermediate Cpd I. Species D resembled C, but with a slight increase in the peak at 416 nm (Fig. S5, Supporting info.).

Oxidation with Stoichiometric Amounts of mCPBA

Oxidation with one molar equivalent of *m*CPBA (enzyme, 5 μ M; *m*CPBA, 5 μ M in 100 mM phosphate buffer, pH 6.2) resulted in significant changes in the absorbance spectra of both the WT and SeCYP119 proteins. Consistent with previous findings, the SVD analysis of the rapid scan spectrum for the oxidation of WT enzyme using the model $A + B \rightarrow C \rightarrow A$ clearly showed the formation of Cpd I (species C), as characterized by its typical absorbance at 369 nm. This was followed by the rapid conversion of Cpd I back to the native ferric protein (Fig. 1A). The calculated spectrum correlated well with the previously reported Cpd I spectrum of the WT enzyme (3,22). Kinetic traces of the reaction revealed a rapid formation of the intermediate Cpd I (at 369 nm) within a few milliseconds followed by its decay. Similarly, the ferric absorbance at 416 nm decreased rapidly followed by a recovery within a few milliseconds (Fig. 1B). The global analysis yielded a second order rate constant (k_1) of $2.6 \times 10^6 \text{ M}^{-1} \text{ s}^{-1}$ for the formation of Cpd I and a first order rate constant (k_2) of 14.2 s^{-1} for its decay. The corresponding values determined earlier at 4 °C rather than 10 °C were $4.28 \times 10^5 \text{ M}^{-1} \text{ s}^{-1}$ and 22 s^{-1} , respectively (22).

In contrast, accumulation of Cpd I was not observed in the oxidation of SeCYP119 with *m*CPBA under similar conditions. While very little change in the absorbance at 369 nm was observed, the Soret band shifted from 416 to 414 nm over 0.9 s. The SVD analysis of the data using the model $A + B \rightarrow C \rightarrow D$, with $k_1 = 3.4 \times 10^6 \text{ M}^{-1} \text{ s}^{-1}$ and $k_2 = 1.1 \text{ s}^{-1}$ yielded a spectrum with a species C resembling the starting ferric enzyme except for a 1-nm blue shift of the Soret peak (Fig. 2A). Species D showed a further blue shift of the Soret

band to 414 nm along with a new broad shoulder at 625 nm and characteristic α and β bands at 556 and 525 nm (Fig. 2A). The kinetic traces at 369 nm further indicated very little or no formation of Cpd I, while the 416 nm trace (ferric protein) slowly decreased in absorbance over time (Fig. 2B). The apparent second-order rate constant for the initial reaction of SeCYP119 with *m*CPBA (k_{app}) was comparable to the reaction of *m*CPBA with the WT protein. Similar results were obtained even when the oxidation was carried out at varying pH values (7.0 and 7.8). These results may suggest a highly reactive Cpd I intermediate, accompanied by a possible change in the heme environment of the SeCYP119 protein.

Oxidation with Excess *m*CPBA

We monitored the oxidation in the presence of excess *m*CPBA based on the premise that increasing the rate of formation of Cpd I might help us resolve the kinetics of Cpd I formation and decay. However, the oxidation of SeCYP119 with five equivalents of oxidant again did not give rise to the detectable formation of Cpd I. The rapid scan absorbance spectrum obtained within 0.9 s of the reaction revealed a significant shift in the ferric absorbance at 416 nm, together with a modest decrease in the absorbance of the α - and β -bands in the visible region, with no evidence of Cpd I formation (Fig. 3A). However, a clear blue shift in absorbance was noticed when the reaction was monitored over 2.25 s (Fig 3A, *Inset*) that competed with heme destruction. The SVD analysis of the data from initial 0.9 s, using the model $A + B \rightarrow C \rightarrow D$ with $k_1 = 2.62 \times 10^6 \text{ M}^{-1} \text{ s}^{-1}$ and $k_2 = 0.52 \text{ s}^{-1}$, revealed a species C that was identical to the untreated enzyme, but with a 2-nm shift in absorbance from 416 to 414 nm (Fig. 3B). Interestingly, a new species D was observed with a Soret maximum at 406 nm. We suspected it to be a species reflecting heme loss. However, species D in SeCYP119 displayed a 10-nm blue shift from the starting ferric spectrum with a minimal loss in the absorbance maximum at 406 nm (Fig. 3B). Similar results were obtained when the oxidation was carried out with a ten-equivalent excess of *m*CPBA (data not shown). The final 406 nm species was stable over a period of at least 2 min under stopped flow conditions. More importantly, the absorbance at 406 nm did not undergo a further blue shift upon addition of excess *m*CPBA but resulted in loss of the absorbance maximum at 406 nm, consistent with possible heme destruction. Overall, increasing the expected rate of formation of Cpd I did not lead to an increase in detectable levels of Cpd I in SeCYP119. This suggests that Cpd I is either not formed or decays faster than it is formed.

In an effort to observe the formation of Cpd I in SeCYP119, oxidation of the enzyme was carried out in the presence of the substrate lauric acid. The SeCYP119 was pre-incubated with lauric acid (50 μM) for 2 min and the resulting solution was rapidly mixed with excess *m*CPBA in the stopped-flow instrument. No significant build up of Cpd I was detected, as the oxidation led directly to the 406 nm species (data not shown). However, there was an ~ 2 fold decrease in the rate of formation of the 406 nm species, which may reflect competition between the oxidant and the lauric acid for binding within the active site.

Absence of Covalent Heme Binding

Replacement of the proximal histidine by a selenocysteine in human heme oxygenase-1 results in covalent attachment of the selenocysteine to one of the heme vinyl groups (20). The covalently modified heme had an absorption maximum at around 402 nm (20). We therefore investigated whether the 406 nm species, from here on referred to as P406, might represent a heme covalently attached to the protein. To test for this, the initially generated P406 was subjected to chromatography on a reverse phase C4 HPLC column with monitoring of the heme and protein at 400 and 280 nm, respectively. Normally, the prosthetic heme and the protein elute at different retention times, but in the event of covalent bond formation, the heme coelutes with the protein. In fact, the heme and protein of P406 eluted separately at 20 and 36 min, respectively (Fig. S6, Supporting info.). Furthermore, the

amount of the eluted heme decreased significantly at higher concentrations of *m*CPBA (from 10 to 20 equivalents), consistent with more extensive oxidative heme destruction. Similar results were observed when the WT CYP119 protein was oxidized and separated by HPLC under identical conditions. Our findings establish that the prosthetic heme in P406 is not covalently attached to the protein.

Catalytic Activity of P406

The ability of P406 to oxidize lauric acid was examined in the presence of excess *m*CPBA. SeCYP119 was initially oxidized to the P406 species, which was then incubated with lauric acid (100 μ M) followed by the addition of excess *m*CPBA (100 μ M). The reaction was allowed to proceed either at room temperature or at 50 °C and the resulting products were extracted and analyzed by GC-MS. Interestingly, no lauric acid oxidation products were detected under these conditions (Fig. S6, Supporting info.). However, hydroxylation of the lauric acid was observed when the enzyme was pre-incubated with the substrate prior to the addition of any *m*CPBA. Previously, SeCYP119 was shown to oxidize lauric acid to the ω and ω -1 hydroxylation products in the presence of excess H₂O₂ (15). Nevertheless, use of H₂O₂ (10 mM) in the P406-mediated oxidation of lauric acid under similar conditions also failed to generate the expected oxidation products. Indeed, the P406 species did not react with lauric acid, as the substrate was fully recovered after the incubation. These results indicate that P406 is not catalytically active.

UV-vis Characteristics of P406

Given the stability of P406, it was not necessary to use stopped-flow for further studies. We therefore investigated the properties of this species by UV-vis spectroscopy under normal room temperature conditions. Consistent with our expectations, P406 was formed immediately (See materials and methods for P406 generation) and was observed to be stable for at least 5 min at room temperature (Fig. 4A). More importantly, the peak at 406 nm did not undergo a decrease in absorbance over this time period, suggesting that heme destruction was minimal. In contrast, oxidation of WT CYP119 with ten equivalents of *m*CPBA resulted in a huge decrease in the Soret maximum at 416 nm, consistent with almost quantitative heme loss (Fig. 4B). Estimation of the remaining heme using the pyridine hemochromogen assay indicated a loss of no more than 40% of the total heme content upon oxidation of SeCYP119 with ten equivalents *m*CPBA, whereas the WT enzyme lost more than 90% of its heme under the same conditions. These results suggest that SeCYP119 is much more resistant to oxidative heme loss than the WT enzyme.

We investigated the nature of the heme in P406 by adding a type II inhibitor, 4-phenylimidazole. Coordination of the nitrogen of the azole to the ferric heme iron atom should result in a red-shift of the Soret band from 416 to 424 nm in the absolute spectrum (31). Addition of 4-phenylimidazole (100–200 μ M) to P406 resulted in a small 2 nm red shift in the absolute spectrum, inconsistent with the binding of a typical type II ligand to the native ferric heme (Fig. 4A). We then also determined if the ferrous heme can bind carbon monoxide to yield a typical P450 spectrum. The P406 protein was flushed with carbon monoxide (Airgas, CA) followed by the addition of sodium dithionite. A peak at 422 nm in the difference spectrum was immediately formed that then underwent complete time-dependent conversion over 5–10 min to an Fe(II)-CO complex with a maximum at 456 nm (Fig. 4C). This suggests that the heme iron in P406 is in the ferric state. In order to determine whether molecular oxygen and/or reactive oxygen species were involved in the formation of the P406 intermediate, we conducted the *m*CPBA-mediated oxidation of SeCYP119 under strictly anaerobic conditions in a glove box. Interestingly, P406 was generated even under anaerobic conditions, indicating that molecular oxygen is not required for its formation.

In an effort to further characterize the reversible modification that occurred in the active site, P406 generated under anaerobic conditions was denatured and reduced using DTT, followed by alkylation with iodoacetamide. The resulting protein was subjected to trypsin digestion and the peptides were analyzed by LC/MS/MS. The active site peptide of the native SeCYP119 protein showed the expected isotopic distribution with an m/z of 600.9(5+) (first “visible” isotope peak) corresponding to the expected carbamidomethylated selenocysteine-containing peptide. Unfortunately, no oxidized form of the selenocysteine-containing peptide was observed upon trypsin digestion and LC/MS/MS analysis of the P406 protein. The only peptide observed was the alkylated selenocysteine-containing molecule (m/z 600.9(5+)) as in the tryptic digest of the native protein (Fig. S7, Supporting info.). We reasoned that if SeCys had undergone an oxidative modification, it was reversed by DTT. As expected, reduction of the P406 protein in the presence of excess DTT (10 mM) resulted in an immediate red shift of the Soret maximum from 406 to 417 nm (Fig. 4D). More importantly, DTT-mediated reduction led to regeneration of the signature α - and β -bands of heme, indicating the presence of a native six-coordinated ferric heme containing SeCys as its proximal ligand (Fig. 4D). Furthermore, CO did not bind to the DTT-treated enzyme, indicating that the heme iron was not reduced by the DTT. However, addition of sodium dithionite resulted in immediate generation of the conventional 456 nm spectrum.

Formation of Cpd II in the Peroxynitrite-Mediated Oxidation of SeCYP119

We investigated the reaction of PN with the SeCYP119 protein to determine whether a Cpd II species was formed. Intriguingly, oxidation of SeCYP119 with excess PN generated a species with an absorbance maximum at 433 nm. PN-mediated oxidation of chloroperoxidase is reported to generate an analogous species with an absorbance maximum at 433 nm that has been attributed to a Cpd II intermediate containing a neutral Fe(IV)-oxo species with the iron one oxidizing equivalent above the resting ferric state (32,33). Oxidation of WT CYP119 with PN under identical conditions yielded a similar species with a maximum at 429 nm, as reported earlier (data not shown) (23). Although the exact nature of this intermediate has been the subject of some controversy (34), we will refer to our 433 nm intermediate as Cpd II based on its similarity with the Cpd II of chloroperoxidase.

Reaction of SeCYP119 with PN leads to a decrease in the absorbance at 416 nm of the resting ferric enzyme with a concomitant increase in the peak at 433 nm that corresponds to Cpd II (Fig. 5A). The SVD analysis of the rapid scan absorbance data for the initial 1 s with the $A \rightarrow B \rightarrow C$ model, fitted with $k_1 = 22 \text{ s}^{-1}$ and $k_2 = 3 \text{ s}^{-1}$ (at 0.5 mM PN) revealed the presence of an intermediate B that appeared to be an SeCYP119 complex with the PN, which then apparently underwent a homolytic cleavage to yield the final Cpd II species C with an absorbance maximum at 433 nm (Fig. 5B). The initial reaction of SeCYP119 with PN increased with increasing concentrations of PN, as expected for a bi-molecular reaction. The apparent pseudo first order rate constant for the formation of Cpd II, k_2 , did not show any dependence on the PN concentration, consistent with a uni-molecular reaction. The Cpd II intermediate was stable as long as PN was present, but began to decay back to the native ferric protein once the PN was consumed. The pseudo first order rate constants obtained from the SVD analysis were plotted against the PN concentration to obtain the second order rate constant for the reaction of PN with SeCYP119. Our data yields a rate constant of $1.6 (\pm 0.3) \times 10^4 \text{ M}^{-1} \text{ s}^{-1}$ that is approximately 2.5 fold slower than that obtained for the reaction of PN with WT CYP119 under similar conditions.

Cpd II of SeCYP119 decayed more slowly than that of the WT protein to regenerate the ferric protein, as judged from their respective kinetic traces at 433 nm and 430 nm (Fig. 5C). The stability of Cpd II depends on the concentration of PN present in the solution. Following the decay of PN at 306 nm revealed that the rate of PN consumption was comparable in both the WT and SeCYP119 reactions, with the concentration of PN

approaching the baseline at around 25–30 s (Fig. 5D). This suggests that the stability of Cpd II in the seleno protein is not due to the presence of excess PN. Furthermore, the species at 416 nm regenerated from Cpd II was identified as the native ferric protein by its characteristic binding to the type II inhibitor, 4-phenylimidazole. Overall, oxidation of SeCYP119 with PN led to the generation of Cpd II with a small 3 nm red shift compared to that of the WT CYP119 equivalent. More importantly, Cpd II was reduced back to the native ferric protein in a way similar to that observed for WT CYP119.

DISCUSSION

We investigated the physical properties of SeCYP119 to determine to what extent they are altered by replacement of the proximal cysteine thiolate by a larger, more electron donating, ligand. CYP119, a thermophilic P450, is remarkably more stable than mesophilic P450 enzymes. Replacement of the active site cysteine by a selenocysteine did not alter the thermal stability of the enzyme. Some of the thermal stability of CYP119 is due to stacking interactions of aromatic residues at the protein surface (35), but the insensitivity of the thermal stability to the selenolate for thiolate substitution is surprising. Similarly, the MCD spectra of the ferric and ferrous states of WT CYP119 and SeCYP119 exhibit no significant differences, confirming our previous conclusion from EPR and resonance Raman data that the electronic nature at the heme center in the seleno protein is very similar to that of the WT enzyme (16). However, the redox potential of –265 mV for SeCYP119 is approximately 51 mV lower than that of WT CYP119, in close accord with the redox potential difference of 48 mV between CYP101A1 and SeCYP101A1 (17). A second phase observed in the redox potential titration with a potential of –67 mV cannot be unambiguously assigned. This potential corresponds to a less electron donating proximal ligand and could possibly reflect the presence of some oxidized selenolate ligand. Thus, although the structural properties of CYP119 are minimally perturbed by the selenocysteine replacement, it causes a substantial change in the redox potential.

In view of the change in redox potential, the role of the electron rich selenocysteine ligand in the kinetics of Cpd I formation was investigated. Formation of Cpd I has been characterized by SVD analysis of the oxidation of WT CYP119 by *m*CPBA (22). Oxidation of WT CYP119 with sub-stoichiometric amounts of *m*CPBA generated a Cpd I intermediate with absorption maxima at 370, 610 and 690 nm (3,22). The Cpd I spectrum was calculated from SVD analysis of the rapid scan data in which the protein underwent little reaction under limiting peracid conditions (22). In our hands, oxidation of WT CYP119 with stoichiometric and sub-stoichiometric concentrations of *m*CPBA produced an intermediate in the SVD analysis with spectral characteristics similar to those of the previously reported Cpd I (3,22). Interestingly, oxidation of SeCYP119 under similar conditions did not yield a detectable Cpd I. The overall change in absorbance in the reaction of SeCYP119 with *m*CPBA was very small compared to the reaction of WT CYP119 under the same conditions and the SVD analysis of the data using various kinetic models failed to generate a characteristic Cpd I intermediate. This suggests three possibilities: *a*) SeCYP119 does not react with *m*CPBA, *b*) the reaction occurs but Cpd I is not formed, or *c*) Cpd I is formed but is very quickly reduced to the ferric state. While SeCYP119 reacted to about a three-fold lesser extent (~6%) compared to the WT enzyme (~17%), as judged by the overall change in the absorbance with 1 equivalent of *m*CPBA, the amount of SeCYP119 that reacted should suffice to observe Cpd I in the SVD analysis. Furthermore, the fact that SeCYP119 catalyzes lauric acid hydroxylation in the presence of excess H₂O₂ (15) or *m*CPBA clearly suggests the formation of a Cpd I intermediate. Thus, we infer that the reaction of SeCYP119 with *m*CPBA yields an intermediate, presumably a seleno Cpd I, that is too rapidly reduced to be detected. Based on the SVD analysis, the apparent rate constant for the reaction of *m*CPBA with SeCYP119 was estimated to be $3.4 \times 10^6 \text{ M}^{-1} \text{ s}^{-1}$. However, this value has to be

interpreted carefully as it may involve multiple reactions.¹ More importantly, the estimated rate constant (k_{app}) represents the slower step in the kinetics and, as Cpd I was not observed, this is presumably the initial reaction of *m*CPBA with SeCYP119. Our data indicate that *m*CPBA reacts with SeCYP119 at a rate comparable to that of the WT enzyme.

With low concentrations of the oxidant, it is possible that Cpd I decayed faster than it was formed, precluding its accumulation and spectroscopic observation. We therefore increased the rate of formation of Cpd I by increasing the concentration of the oxidant. Although these conditions cause some heme destruction, excess *m*CPBA has been used before in the oxidation of CYP101A1 to detect the formation of a Cpd I like species (36). However, Cpd I was not detected in the SVD analysis when SeCYP119 was oxidized with five- or ten-equivalent excesses of *m*CPBA. Our various attempts to detect the formation of Cpd I, including *a*) oxidation at higher pH (pH 7.0 and 7.8), *b*) using peroxyacetic acid as an alternate oxidizing agent, and *c*) oxidation in the presence of lauric acid failed to yield a detectable Cpd I intermediate. Taken together, these results argue for the formation in SeCYP119 of a Cpd I intermediate that decays faster than it is formed. It is likely that the electron-rich selenolate ligand reduces Cpd I as it is formed.

Reaction of SeCYP119 with excess *m*CPBA generated a species with a Soret maximum at 406 nm (P406) that is ~ 10 nm blue-shifted from the absorption maximum of the native ferric protein. Surprisingly, only 40% of the heme was lost during the oxidation of SeCYP119. Thus, SeCYP119 is much more resistant to heme destruction than the WT protein. The active site of SeCYP119 has clearly undergone an unprecedented oxidative modification that effectively competes with the heme destruction pathway. The nature of this P406 species is discussed below.

An intermediate with an absorption maximum at 406 nm has been encountered in the *m*CPBA-mediated oxidation of CYP101A1 (37), P450_{BM3} (38), and more recently CYP153A6 from *Mycobacterium* sp. HXN-1500 (39). This intermediate was assigned to Cpd ES with a neutral (or protonated) Fe(IV)=O species and a radical located on a nearby tyrosine or tryptophan residue (40,41). Importantly, Cpd ES is relatively rapidly reduced to the native ferric state in a process that is accelerated by mild reducing agents such as ascorbic acid or guaiacol. In contrast, addition of ascorbic acid (1 mM final concentration) to the SeCYP119 P406 species did not alter the absorbance spectrum. Thus, although the UV-vis spectral properties of SeCYP119 P406 are similar to those observed in the reaction of *m*CPBA with CYP101A1, its stability to mild reducing agents clearly differentiates it from a Cpd ES.

Oxidation of SeCYP119 with peroxynitrite (PN) generated a Cpd II like intermediate (neutral Fe(IV)=O species) similar to that of the WT enzyme. SeCYP119 reacts more slowly with PN than does WT CYP119, but the resulting Cpd II is more stable. Importantly, Cpd II decayed back to the native ferric protein without forming a P406 intermediate, presumably because Cpd II is not as highly oxidizing as Cpd I. The P406 intermediate thus derives from a reaction intermediate other than Cpd II.

Reduction of SeCYP119 P406 with dithionite in the presence of carbon monoxide immediately yielded a 422 nm peak in the difference spectrum that subsequently underwent complete, time-dependent conversion over 5–10 min to an Fe(II)-CO spectrum with a maximum at 456 nm identical to that of the original SeCYP119. These changes indicate that

¹The SeCYP119 is not completely pure and contains a small amount (< 20%) of the WT enzyme. However, contributions from the WT to the kinetics of Cpd I formation are negligible, since we do not observe any traces of Cpd I formation at the concentrations of the *m*CPBA used.

the structural features that cause the 406 nm maximum are eliminated upon reduction with sodium dithionite. Based on these results, we speculate that P406 has a six-coordinated low spin ferric heme with an oxidatively modified proximal selenocysteine ligand that is reduced by dithionite back to selenocysteine. Consistent with this hypothesis, DTT, a thiol based reducing agent, reduced the chromophore in P406 to the native ferric heme with its normal coordination and its signature α and β bands. Treatment with DTT apparently reduced the oxidatively modified proximal SeCys without reducing the heme iron atom. Restoration of the native protein by DTT was supported by an LC/MS/MS spectrum of the trypsin digested P406 species that revealed an alkylated SeCys active site peptide identical to that of SeCYP119 not exposed to *m*CPBA. Taken together, these results strongly argue that P406 is a pure species containing an oxidatively modified active site that is completely reduced by treatment with dithionite or DTT to regenerate the native SeCYP119 protein.

It is tempting from our findings to propose oxidation of the SeCys to the selenenic acid (Se-OH), as this oxidation would be reversed by reducing agents such as dithionite and DTT. Our results rule out the presence of irreversibly oxidized forms of the proximal SeCys ligand such as SeO₂H and SeO₃H, as these should not be reduced by DTT and dithionite. Our attempts to trap a selenenic acid species using 4-chloro-7-nitrobenzo-2-oxa-1,3-diazol (NBD-Cl) have been unsuccessful. The proximal SeCys is deeply buried in the proximal side of the active site and is not readily accessible to NBD. However, we cannot rule out an intra-molecular protein cross-link to form something like a selenenyl amide with the neighboring lysine residue. Thus, an alternate pathway is proposed that involves oxidation of the proximal SeCys to generate a stable two electron oxidized species that competes with heme destruction (Scheme 1). The exact mechanism for this transformation is not clear at the moment. Selenols (pKa ~ 5.2) are more acidic than thiols (pKa ~ 8.7) and hence are deprotonated under physiological conditions (42). In addition, the one electron reduction potential of SeCys is approximately 0.5 V lower than that of cysteine (43,44) and hence SeCys should reduce Cpd I more easily than the cysteine thiolate.

Strikingly, while weaker proximal electron donors like histidine fail to support the basic spectral and catalytic properties of a P450 enzyme, a stronger electron donating selenium ligand maintains the spectroscopic characteristics but yields a less active enzyme (15). The two-fold lesser specific activity of SeCYP119 may reflect oxidation of the selenolate ligand. MCD studies indicate that the hydrogen bonding network in the proximal cysteine pocket of CYP101A1 protects the cysteine ligand from oxidation (45). The more acidic selenolate in SeCYP119 may disrupt this hydrogen bonding network, or simply as a result of its more oxidizable nature may not be efficiently protected against oxidation by the active site environment.

In conclusion, SeCYP119 has comparable physical properties to WT CYP119. However, the *m*CPBA-mediated shunt pathway does not generate a detectable Cpd I under conditions that allowed its observation with the WT protein, probably because the Cpd I intermediate is rapidly reduced by the selenolate ligand. Interestingly, oxidation with excess *m*CPBA produced a stable species with an absorption maximum at 406 nm that was (a) unable to catalyze substrate oxidation when exposed to peroxides and lauric acid, (b) resistant to heme destruction, (c) unable to interact with azoles, (d) reduced to the normal, unmodified ferrous state by dithionite, and (e) reduced to the normal, unmodified ferric state by DTT. P406 is thus a novel, reversible, intermediate so far unique to SeCYP119 that may involve two electron oxidation of the proximal selenolate ligand. The results also establish the remarkable extent to which the active site and chemistry of P450 enzymes is uniquely attuned to the thiolate ligand, with ligands of higher or lower electron donating ability impairing function.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Abbreviations and Textual Footnotes

WT	wild-type
SeCYP119	selenocysteine-substituted CYP119
P406	oxidized SeCYP119 species absorbing at 406 nm
SeCys	selenocysteine
CYP101A1 (P450cam)	P450 enzyme from <i>Pseudomonas putida</i>
mCPBA	<i>meta</i> -chloroperbenzoic acid
PN	peroxynitrite
DTT	dithiothreitol
BSTFA	N,O-bis-trimethylsilyl-trifluoroacetamide
GC	gas chromatography
QM/MM	Quantum mechanical/Molecular mechanical
SVD	single value decomposition

Acknowledgments

We thank Mr. David Maltby at the Mass Spectrometry Facility for helpful assistance.

REFERENCES

- Ortiz de Montellano, PR. Cytochrome P450: Structure, Mechanism and Biochemistry. third ed.. New York: Kluwer Academic/Plenum Publishers; 2005.
- Ortiz de Montellano PR. Hydrocarbon hydroxylation by cytochrome P450 enzymes. Chem. Rev. 2010; 110:932–948. [PubMed: 19769330]
- Rittle J, Green MT. Cytochrome P450 compound I: capture, characterization, and C-H bond activation kinetics. Science. 330:933–937. [PubMed: 21071661]
- Poulos, TL.; Johnson, EF. Structures of Cytochrome P450 enzymes. third ed.. New York: Kluwer Elsevier; 2005.
- Dawson JH, Sono M. Cytochrome P-450 and chloroperoxidase: thiolate-ligated heme enzymes. Spectroscopic determination of their active-site structures and mechanistic implications of thiolate ligation. Chem. Rev. 1987; 87:1255–1276.
- Yoshioka S, Takahashi S, Hori H, Ishimori K, Morishima I. Proximal cysteine residue is essential for the enzymatic activities of cytochrome P450cam. Eur. J. Biochem. 2001; 268:252–259. [PubMed: 11168358]
- Auclair K, Moenne-Loccoz P, Ortiz de Montellano PR. Roles of the proximal heme thiolate ligand in cytochrome p450(cam). J. Am. Chem. Soc. 2001; 123:4877–4885. [PubMed: 11457314]
- Vatsis KP, Peng HM, Coon MJ. Replacement of active-site cysteine-436 by serine converts cytochrome P450 2B4 into an NADPH oxidase with negligible monooxygenase activity. J. Inorg. Biochem. 2002; 91:542–553. [PubMed: 12237221]
- Murugan R, Mazumdar S. Structure and redox properties of the haem centre in the C357M mutant of cytochrome P450cam. Chembiochem. 2005; 6:1204–1211. [PubMed: 15912551]
- Cohen S, Kumar D, Shaik S. In silico design of a mutant of cytochrome P450 containing selenocysteine. J. Am. Chem. Soc. 2006; 128:2649–2653. [PubMed: 16492051]

11. Nishida CR, Ortiz de Montellano PR. Thermophilic cytochrome P450 enzymes. *Biochem. Biophys. Res. Commun.* 2005; 338:437–445. [PubMed: 16139791]
12. Hondal RJ, Raines RT. Semisynthesis of proteins containing selenocysteine. *Methods Enzymol.* 2002; 347:70–83. [PubMed: 11898440]
13. Wu ZP, Hilvert D. Conversion of a protease into an acyl transferase: selenolsubtilisin. *J. Am. Chem. Soc.* 1989; 111:4513–4514.
14. Arner ES, Sarioglu H, Lottspeich F, Holmgren A, Bock A. High-level expression in *Escherichia coli* of selenocysteine-containing rat thioredoxin reductase utilizing gene fusions with engineered bacterial-type SECIS elements and co-expression with the selA, selB and selC genes. *J. Mol. Biol.* 1999; 292:1003–1016. [PubMed: 10512699]
15. Jiang Y, Sivaramakrishnan S, Hayashi T, Cohen S, Moenne-Loccoz P, Shaik S, Ortiz de Montellano PR. Calculated and experimental spin state of seleno cytochrome P450. *Angew. Chem. Int. Ed. Engl.* 2009; 48:7193–7195. [PubMed: 19718734]
16. Muller S, Senn H, Gsell B, Vetter W, Baron C, Bock A. The formation of diselenide bridges in proteins by incorporation of selenocysteine residues: biosynthesis and characterization of (Se)2-thioredoxin. *Biochemistry.* 1994; 33:3404–3412. [PubMed: 8136378]
17. Aldag C, Gromov IA, Garcia-Rubio I, von Koenig K, Schlichting I, Jaun B, Hilvert D. Probing the role of the proximal heme ligand in cytochrome P450cam by recombinant incorporation of selenocysteine. *Proc. Natl. Acad. Sci. U S A.* 2009; 106:5481–5486. [PubMed: 19293375]
18. Ramette R, Sandford RW Jr. Thermodynamics of Iodine Solubility and Triiodide Ion Formation in Water and in Deuterium Oxide. *J. Am. Chem. Soc.* 1965; 87:5001–5005.
19. Uppu RM, Pryor WA. Synthesis of peroxynitrite in a two-phase system using isoamyl nitrite and hydrogen peroxide. *Anal. Biochem.* 1996; 236:242–249.
20. Jiang Y, Trnka MJ, Medzihradsky KF, Ouellet H, Wang Y, Ortiz de Montellano PR. Covalent heme attachment to the protein in human heme oxygenase-1 with selenocysteine replacing the His25 proximal iron ligand. *J. Inorg. Biochem.* 2009; 103:316–325. [PubMed: 19135260]
21. Huff AM, Change CK, Cooper DK, Smith KM, Dawson JH. Imidazole- and alkylamine-ligated iron(II,III) chlorin complexes as models for histidine and lysine coordination to iron in dihydroporphyrin-containing proteins: characterization with magnetic circular dichroism spectroscopy. *Inorg. Chem.* 1993; 32:1460–1466.
22. Kellner DG, Hung SC, Weiss KE, Sligar SG. Kinetic characterization of compound I formation in the thermostable cytochrome P450 CYP119. *J. Biol. Chem.* 2002; 277:9641–9644. [PubMed: 11799104]
23. Newcomb M, Zhang R, Chandrasena RE, Halgrimson JA, Horner JH, Makris TM, Sligar SG. Cytochrome p450 compound I. *J. Am. Chem. Soc.* 2006; 128:4580–4581. [PubMed: 16594688]
24. Meitzler JL, Ortiz de Montellano PR. *Caenorhabditis elegans* and human dual oxidase 1 (DUOX1) "peroxidase" domains: insights into heme binding and catalytic activity. *J. Biol. Chem.* 2009; 284:18634–18643. [PubMed: 19460756]
25. Daff SN, Chapman SK, Turner KL, Holt RA, Govindaraj S, Poulos TL, Munro AW. Redox control of the catalytic cycle of flavocytochrome P-450 BM3. *Biochemistry.* 1997; 36:13816–13823. [PubMed: 9374858]
26. Dutton PL. Redox potentiometry: determination of midpoint potentials of oxidation-reduction components of biological electron-transfer systems. *Methods Enzymol.* 1978; 54:411–435. [PubMed: 732578]
27. Lawson RJ, Leys D, Sutcliffe MJ, Kemp CA, Cheesman MR, Smith SJ, Clarkson J, Smith WE, Haq I, Perkins JB, Munro AW. Thermodynamic and biophysical characterization of cytochrome P450 BioI from *Bacillus subtilis*. *Biochemistry.* 2004; 43:12410–12426. [PubMed: 15449931]
28. Koo LS, Tschirret-Guth RA, Straub WE, Moenne-Loccoz P, Loehr TM, Ortiz de Montellano PR. The active site of the thermophilic CYP119 from *Sulfolobus solfataricus*. *J. Biol. Chem.* 2000; 275:14112–14123. [PubMed: 10799487]
29. Metanis N, Keinan E, Dawson PE. Synthetic seleno-glutaredoxin 3 analogues are highly reducing oxidoreductases with enhanced catalytic efficiency. *J. Am. Chem. Soc.* 2006; 128:16684–16691. [PubMed: 17177418]

30. Casi G, Roelfes G, Hilvert D. Selenogluta-redoxin as a glutathione peroxidase mimic. *Chembiochem.* 2008; 9:1623–1631. [PubMed: 18548475]
31. Lampe JN, Floor SN, Gross JD, Nishida CR, Jiang Y, Trnka MJ, Ortiz de Montellano PR. Ligand-induced conformational heterogeneity of cytochrome P450 CYP119 identified by 2D NMR spectroscopy with the unnatural amino acid (13)C-p-methoxyphenylalanine. *J. Am. Chem. Soc.* 2008; 130:16168–16169. [PubMed: 18998650]
32. Nakajima R, Yamazaki I, Griffin BW. Spectra of chloroperoxidase compounds II and III. *Biochem. Biophys. Res. Commun.* 1985; 128:1–6. [PubMed: 3985960]
33. Daiber A, Herold S, Schoneich C, Namgaladze D, Peterson JA, Ullrich V. Nitration and inactivation of cytochrome P450BM-3 by peroxy-nitrite. Stopped-flow measurements prove ferryl intermediates. *Eur. J. Biochem.* 2000; 267:6729–6739. [PubMed: 11082183]
34. Behan RK, Hoffart LM, Stone KL, Krebs C, Green MT. Reaction of cytochrome P450BM3 and peroxy-nitrite yields nitrosyl complex. *J. Am. Chem. Soc.* 2007; 129:5855–5859. [PubMed: 17432853]
35. Puchkaev AV, Koo LS, Ortiz de Montellano PR. Aromatic stacking as a determinant of the thermal stability of CYP119 from *Sulfolobus solfataricus*. *Arch. Biochem. Biophys.* 2003; 409:52–58. [PubMed: 12464244]
36. Spolitat T, Dawson JH, Ballou DP. Reaction of ferric cytochrome P450cam with peracids: kinetic characterization of intermediates on the reaction pathway. *J. Biol. Chem.* 2005; 280:20300–20309. [PubMed: 15781454]
37. Spolitat T, Dawson JH, Ballou DP. Rapid kinetics investigations of peracid oxidation of ferric cytochrome P450cam: nature and possible function of compound ES. *J. Inorg. Biochem.* 2006; 100:2034–2044. [PubMed: 17095096]
38. Raner GM, Thompson JI, Haddy A, Tangham V, Bynum N, Ramachandra Reddy G, Ballou DP, Dawson JH. Spectroscopic investigations of intermediates in the reaction of cytochrome P450(BM3)-F87G with surrogate oxygen atom donors. *J. Inorg. Biochem.* 2006; 100:2045–2053. [PubMed: 17083977]
39. Spolitat T, Funhoff EG, Ballou DP. Spectroscopic studies of the oxidation of ferric CYP153A6 by peracids: Insights into P450 higher oxidation states. *Arch. Biochem. Biophys.* 493:184–191. [PubMed: 19879854]
40. Schunemann V, Jung C, Turner J, Trautwein AX, Weiss R. Spectroscopic studies of peroxyacetic acid reaction intermediates of cytochrome P450cam and chloroperoxidase. *J. Inorg. Biochem.* 2002; 91:586–596. [PubMed: 12237224]
41. Schunemann V, Lendzian F, Jung C, Contzen J, Barra AL, Sligar SG, Trautwein AX. Tyrosine radical formation in the reaction of wild type and mutant cytochrome P450cam with peroxy acids: a multifrequency EPR study of intermediates on the millisecond time scale. *J. Biol. Chem.* 2004; 279:10919–10930. [PubMed: 14688245]
42. Huber RE, Criddle RS. Comparison of the chemical properties of selenocysteine and selenocystine with their sulfur analogs. *Arch. Biochem. Biophys.* 1967; 122:164–173. [PubMed: 6076213]
43. Jacob C, Giles GI, Giles NM, Sies H. Sulfur and selenium: the role of oxidation state in protein structure and function. *Angew. Chem. Int. Ed. Engl.* 2003; 42:4742–4758. [PubMed: 14562341]
44. Nauser T, Dockheer S, Kissner R, Koppenol WH. Catalysis of electron transfer by selenocysteine. *Biochemistry.* 2006; 45:6038–6043. [PubMed: 16681376]
45. Galinato MG, Spolitat T, Ballou DP, Lehnert N. Elucidating the Role of the Proximal Cysteine Hydrogen Bonding Network in Ferric Cytochrome P450cam and corresponding mutants using Magnetic Circular Dichroism Spectroscopy. *Biochemistry.* In Press.

Figure 1.

Spectral characterization of WT CYP119 (5 μM) upon mixing with one equivalent of *m*CPBA (100 mM KPi, pH 6.2 at 10 $^{\circ}C$): A) calculated spectra from the SVD analysis of the rapid scan absorbance traces for the initial 0.45 s: ferric protein (solid line) and compound I (dashed line); *Inset*, zoom in of the visible region. B) kinetic traces of the ferric (416 nm) and Cpd I (369 nm).

Figure 2. Spectral characterization of SeCYP119 (5 μM) upon mixing with one equivalent of *mCPBA* (100 mM KPi, pH 6.2 at 10 $^{\circ}C$): A) calculated spectra from the SVD analysis of the rapid scan absorbance traces for the initial 0.9 s: A (ferric protein, blue); C (ferric like protein, green); D (ferric like protein with 2 nm blue shift, red), *Inset*, zoom in of the visible region. B) kinetic traces of the ferric (416 nm) and Cpd I (369 nm).

Figure 3.

Spectral characterization of SeCYP119 (5 μ M) upon mixing with five equivalents of *m*CPBA (100 mM KPi, pH 6.2 at 10 $^{\circ}$ C): A) traces of the rapid scan absorbance spectra obtained for the initial 0.9 s, *Inset*, traces of the rapid scan spectra obtained over 2.25 s. B) calculated spectra from the SVD analysis of the rapid scan data of the initial 0.9 s, traces: A (ferric protein, blue); C (ferric like protein, green); D (P406 species, red).

Figure 4.

A) Oxidation of SeCYP119 (5 μM) with 10 equivalents of *m*CPBA (100 mM KPi, pH 6.2 at 24 °C). Spectra shown are native protein (416 nm); 5 min after the addition of 10× *m*CPBA (406 nm) and 2 min after the addition of ~100 μM 4-phenylimidazole (408 nm). B) Oxidation of WT CYP119 before and after the addition of 10× *m*CPBA. C) Fe(II)-CO difference spectrum of the P406 species, monitored over 10 min. D) Oxidation of SeCYP119 to generate P406 species followed by treatment with excess DTT (10 mM) to regenerate the native spectrum. *Inset*, zoom in of the visible region showing the α and β bands of the DTT treated P406.

Figure 5.

Oxidation of SeCYP119 with excess PN. A) rapid scan absorbance traces for the oxidation with 1.5 mM PN over 45 s, showing the conversion of the ferric protein (416 nm) to a Cpd II like species (433 nm) that in turn reverts back to the starting ferric form. B) SVD analysis of the rapid scan data for the reaction with 0.5 mM PN over 1 s, showing the formation of Cpd II, traces: blue, native protein; green, SeCYP119 complex with PN; red, Cpd II like species. C) Kinetic traces of Cpd II for the WT (430 nm) and SeCYP119 (433 nm) monitored over 90 s. D) Kinetic traces for the PN decay over 90 s.

Scheme 1.

Proposed pathway for the reaction of SeCYP119 with *m*CPBA to generate the P406 species